- Home
- MPV vs CHRS Comparison
MPV vs CHRS Comparison
Compare MPV & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPV
- CHRS
- Stock Information
- Founded
- MPV 1988
- CHRS 2010
- Country
- MPV United States
- CHRS United States
- Employees
- MPV N/A
- CHRS N/A
- Industry
- MPV Finance Companies
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MPV Finance
- CHRS Health Care
- Exchange
- MPV Nasdaq
- CHRS Nasdaq
- Market Cap
- MPV 213.6M
- CHRS 84.2M
- IPO Year
- MPV N/A
- CHRS 2014
- Fundamental
- Price
- MPV $19.57
- CHRS $0.85
- Analyst Decision
- MPV
- CHRS Buy
- Analyst Count
- MPV 0
- CHRS 3
- Target Price
- MPV N/A
- CHRS $4.68
- AVG Volume (30 Days)
- MPV 25.2K
- CHRS 1.3M
- Earning Date
- MPV 01-01-0001
- CHRS 08-07-2025
- Dividend Yield
- MPV 8.71%
- CHRS N/A
- EPS Growth
- MPV N/A
- CHRS N/A
- EPS
- MPV 1.71
- CHRS N/A
- Revenue
- MPV N/A
- CHRS $272,251,000.00
- Revenue This Year
- MPV N/A
- CHRS N/A
- Revenue Next Year
- MPV N/A
- CHRS $99.43
- P/E Ratio
- MPV $9.35
- CHRS N/A
- Revenue Growth
- MPV N/A
- CHRS 19.87
- 52 Week Low
- MPV $11.18
- CHRS $0.66
- 52 Week High
- MPV $16.42
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- MPV 56.86
- CHRS 53.52
- Support Level
- MPV $19.33
- CHRS $0.73
- Resistance Level
- MPV $19.96
- CHRS $0.96
- Average True Range (ATR)
- MPV 0.53
- CHRS 0.05
- MACD
- MPV -0.08
- CHRS 0.02
- Stochastic Oscillator
- MPV 48.68
- CHRS 53.92
About MPV Barings Participation Investors
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.